Fact CheckerSign in

NCT07527715Recruiting

Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy

Study on Risk Early Warning of Clinical Prediction Model Based on Multi-Parameter Stress Perfusion Cardiac Magnetic Resonance in Adverse Prognosis of Dilated Cardiomyopathy

Source: ClinicalTrials.gov · Last updated 14 Apr 2026

Brief summary (registry, in English)

Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care. This observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results). The model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals. Beyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.

Status (registry)
Recruiting
Study type
Observational
Enrollment
2000 (estimated)
First submitted
2 Apr 2026
Start date
1 Dec 2021
Primary completion date
1 Dec 2028
Lead sponsor
Shandong Provincial Hospital
NCT number
NCT07527715

What you commit to

  • Study type: Observational
  • Planned participants: 2000
  • From 1 Dec 2021 to the primary completion date, 1 Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • 1.An elevated left ventricular end-diastolic volume indexed to body surface area and reduced LVEF, compared with published age- and gender-specific reference values Exclusion Criteria
  • significant coronary artery disease (CAD), defined as a stenosis of ˃50% in a major coronary artery
  • infiltrative disease
  • valvular cardiomyopathy
  • arrhythmogenic cardiomyopathy
  • congenital heart disease

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Jinan Central Hospital
Coordinator of this site? Confirm its status
JinanChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.